Home › Research › Treatments
Zerebrale Amyloidangiopathie
Robin Jansen, Solveig Henneicke, Sven Guenther Meuth, Stefanie Schreiber. Geriatrie up2date, 2025-10-01
Topic: Amyloid, tau and blood-test diagnosis
All articles of this category (opens in new window) Die zerebrale Amyloidangiopathie (CAA) ist eine Erkrankung, bei der sich beta-Amyloid in den Gefäßwänden des Gehirns ablagert. Sie ist eine bedeutende Ursache für lobäre Hirnblutungen und Demenz. Der Beitrag beleuchtet die Epidemiologie, Pathophysiologie und klinischen Erscheinungsbilder der CAA, einschließlich ihrer inflammatorischen Variante. Zudem werden neueste Erkenntnisse zur iatrogenen CAA und zu Amyloid-assoziierten Bildgebungsabnormalitäten (ARIA) im Zusammenhang mit neuen Alzheimer-Therapien vorgestellt. Kernaussagen Die CAA ist durch Ablagerungen von beta-Amyloid in Gefäßwänden des Gehirns gekennzeichnet und eine Hauptursache für lobäre intrazerebrale Blutungen. Die Prävalenz einer moderaten CAA bei 84-Jährigen wird auf etwa 23% geschätzt, bei Alzheimer-Patienten liegt sie bei 50–80%. Die Pathophysiologie der CAA verläuft in 4 Stadien, von ersten Ablagerungen bis hin zu klinisch symptomatischen Hirnblutungen. Mikroblutungen und kortikale superfiziale Siderose sind charakteristische MRT-Merkmale der CAA. Es gibt zunehmende Evidenz für ein „prionenähnliches Verhalten“ von beta-Amyloid, was zu iatrogener CAA führen kann. ARIA treten bei 40% der Patienten unter Anti-Amyloid-Immuntherapien wie Aducanumab auf und erfordern spezielle Behandlungsstrategien. Die CAA-ri zeigt ähnliche Risikofaktoren wie ARIA, unterscheidet sich aber in Häufigkeit und Schwere der Symptome. Publication History Article published online: 13 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Key findings
- Es gibt zunehmende Evidenz für ein „prionenähnliches Verhalten“ von beta-Amyloid, was zu iatrogener CAA führen kann.
- ARIA treten bei 40% der Patienten unter Anti-Amyloid-Immuntherapien wie Aducanumab auf und erfordern spezielle Behandlungsstrategien.
- Die CAA-ri zeigt ähnliche Risikofaktoren wie ARIA, unterscheidet sich aber in Häufigkeit und Schwere der Symptome.
- Publication History Article published online: 13 October 2025 © 2025.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
This review states that cerebral amyloid angiopathy is a major cause of lobar brain hemorrhage and dementia, and that ARIA occurs in 40% of patients on anti-amyloid immunotherapy such as aducanumab, requiring special management strategies. It describes risks and management considerations but reports no cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 25 of the 97 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Geriatrie up2date) |
| Journal's citation record | 0 / 4 | Geriatrie up2date: journal h-index 3 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Stefanie Schreiber: h-index 38 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 25 of the 97 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Jansen, R., Henneicke, S., Meuth, S. G., & Schreiber, S. (2025). Zerebrale Amyloidangiopathie. Geriatrie up2date. https://doi.org/10.1055/a-2657-2392
Vancouver
Jansen R, Henneicke S, Meuth SG, Schreiber S. Zerebrale Amyloidangiopathie. Geriatrie up2date. 2025. doi:10.1055/a-2657-2392.
BibTeX
@article{jansen2025-3d42aad1,
author = {Jansen, Robin and Henneicke, Solveig and Meuth, Sven Guenther and Schreiber, Stefanie},
title = {{Zerebrale Amyloidangiopathie}},
journal = {Geriatrie up2date},
year = {2025},
doi = {10.1055/a-2657-2392},
url = {https://doi.org/10.1055/a-2657-2392}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.